
We claim:

1. Compounds of the general formula (I), their tautomeric forms, their stereoisomers, regioisomers, their pharmaceutically acceptable salts, ~~and pharmaceutical compositions containing them~~





(I)

wherein 'HET' represents an optionally substituted heteroaryl or a heterocyclic group; 'X' represents the groups selected from $(CH_2)_n$, ~~$O(CH_2)_n$, $S(CH_2)_n$, $SO(CH_2)_n$, $SO_2(CH_2)_n$ or $NR_2(CH_2)_n$ wherein R_2 represents H, (C_1-C_6) linear or branched alkyl or a suitable cycloalkyl group, wherein either the alkyl or cycloalkyl group may be further substituted;~~ n = 0 to 3; 'R_1' represents linear or branched (C_1-C_6) alkyl, cycloalkyl, aryl, groups;

'Y' represents

i) the group NR_3R_4, wherein 'R_3' represents (C_1-C_6) linear or branched alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, hydroxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heterocyclyloxy or heterocyclylalkoxy groups, each of which may be further substituted & 'R_4' represents H, $C_{(1-6)}$ linear or branched alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl or heterocyclylalkyl groups, each of which may be further substituted;

ii) the groups , wherein 'P' represents CH_2, S, SO, SO_2, O, CO or NR_5 wherein R_5 represents H, (C_1-C_6) linear or branched alkyl or cyclo- alkyl groups; 'm' represents integers from1 to 3;

and 'Z' represents either NR_3R_4 or the groups  wherein 'R_3', 'R_4' and 'P' are as defined earlier.

2. The compounds as claimed in claim 1 wherein the substituents on 'HET' represents one or more groups selected from hydrogen or optionally substituted groups selected from (C_1-C_6) linear or branched alkyl, aryl, heteroaryl, cycloalkyl or a heterocyclyl group.
3. The compounds of claim 1 wherein the substituents on 'HET' are selected from (C_1-C_6) linear or branched alkyl, aryl or heteroaryl groups, each of which may be further substituted.
4. The compounds of claim 1 wherein when the groups representing 'HET' is further substituted, the substituents are selected from halogen, alkyl, haloalkyl, alkoxy, sulfanyl derivative, sulfinyl derivatives, sulfonyl derivatives, sulfonyloxy groups.
5. The compounds of formula (I) wherein the groups representing 'HET' is selected from 'HET' are selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thieno piperidinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl groups.
6. The compounds of formula (I) selected from
N-(benzyloxy)-2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-*c*-(3-(9H-carbazol-9-yl)propyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(piperidin-1-yl)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(thiomorpholino)methanone;

(1,1-dioxidothiomorpholino)(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)methanone;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-(piperidin-1-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-thiomorpholinoethyl)-1,3-dioxane-2-carboxamide;

N-(2-(1,1-dioxidothiomorpholino)-2-oxoethyl)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-morpholino-3-oxopropyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-(((tetrahydro-2H-pyran-4-yl)methyl)amino)propyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-thiomorpholinopropyl)-1,3-dioxane-2-carboxamide;

N-(3-(1,1-dioxidothiomorpholino)-3-oxopropyl)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-(piperidin-1-yl)propyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-(4-methylpiperazin-1-yl)-3-oxopropyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-1-phenylbutan-2-yl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(piperidin-1-yl)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(thiomorpholino)methanone;

(1,1-dioxidothiomorpholino)(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)methanone;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-thiomorpholinoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-(piperidin-1-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(3-oxo-1-phenylbutan-2-yl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-((3-oxo-1-phenylbutan-2-yl)amino)ethyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

(5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*t*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

N-benzyloxy-2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxane-2-carboxamide;

1-(2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)methanamine;

(2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-t-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

5-*c*-(3-(9H-carbazol-9-yl)propyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*c*-(3-(10H-phenothiazin-10-yl)propyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(hydroxy)-5-*c*-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(hydroxy)-5-*t*-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

(5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

(5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

N-(benzyloxy)-5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

(5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

(5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

N-(benzyloxy)-2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as claimed in any of the preceding claims and a pharmaceutically acceptable carrier diluent or excipients.
8. A pharmaceutical composition according to claim 7 which is used for the treatment of dyslipidemia and related diseases.
9. A method of treating disorders caused by dyslipidemia and related diseases comprising administering to a patient in need thereof an effective amount of a compound of formula (I) according to any of the preceding claims or its pharmaceutical composition according to any of the preceding claims.
10. The use of a compound of formula (I) or its pharmaceutical composition according to any of the preceding claims for the manufacture of a medicament for the treatment of dyslipidemia and related diseases.
11. A medicine for the treatment of disorders caused by dyslipidemia and related diseases which comprises administering therapeutically effective amount of compound of formula (I) or its pharmaceutical composition as defined in any of the preceding claims to a patient or subject in need thereof.

~~12.A method of selecting small molecule inhibitors of PCSK9 by identifying molecules which bind to the catalytic site of the PCSK9, and subsequently checking the binding potential of the identified molecules to the PCSK9 protein.~~


~~13.The method as claimed in claim 12 wherein the molecules bind to one or more of the amino acids comprising the catalytic triad HIS 226 SER 386 ASP 186 alone or in combination with other amino acids from the catalytic site.~~

~~14.~~12. Small molecules comprising the compounds according to any one of claims 1-6 which bind to the catalytic site of the PCSK9, as inhibitors of PCSK9.

~~15.~~13. Small molecules inhibitors of PCSK9 comprising the compounds according to any one of claims 1-6 which bind to the catalytic site of the PCSK9 protein.

We claim:

1. Compounds of the general formula (I), their tautomeric forms, their stereoisomers, regioisomers, their pharmaceutically acceptable salts,




(I)


wherein 'HET' represents an optionally substituted heteroaryl or a heterocyclic group; 'X' represents the groups selected from $(CH_2)_n$, n = 0 to 3; 'R_1' represents linear or branched (C_1-C_6) alkyl, cycloalkyl, aryl, groups;

'Y' represents

i) the group NR_3R_4, wherein 'R_3' represents (C_1-C_6) linear or branched alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl, heterocyclylalkyl, hydroxy, alkoxy, cycloalkoxy, cycloalkylalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, heterocyclyloxy or heterocyclylalkoxy groups, each of which may be further substituted & 'R_4' represents H, $C_{(1-6)}$ linear or branched alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocyclyl, arylalkyl, heteroarylalkyl or heterocyclylalkyl groups, each of which may be further substituted;

ii) the groups 

, wherein 'P' represents CH_2, S, SO, SO_2, O, CO or NR_5 wherein R_5 represents H, (C_1-C_6) linear or branched alkyl or cyclo- alkyl groups; 'm' represents integers from1 to 3;

and 'Z' represents either NR_3R_4 or the groups 

wherein 'R_3', 'R_4' and 'P' are as defined earlier.

2. The compounds as claimed in claim 1 wherein the substituents on 'HET' represents one or more groups selected from hydrogen or optionally substituted groups selected from (C_1-C_6) linear or branched alkyl, aryl, heteroaryl, cycloalkyl or a heterocyclyl group.

3. The compounds of claim 1 wherein the substituents on 'HET' are selected from (C_1-C_6) linear or branched alkyl, aryl or heteroaryl groups, each of which may be further substituted.

4. The compounds of claim 1 wherein when the groups representing 'HET' is further substituted, the substituents are selected from halogen, alkyl, haloalkyl, alkoxy, sulfanyl derivative, sulfinyl derivatives, sulfonyl derivatives, sulfonyloxy groups.

5. The compounds of formula (I) wherein the groups representing 'HET' is selected from 'HET' are selected from aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl, 2-oxopiperidinyl, 4-oxopiperidinyl, 2-oxopiperazinyl, 3-oxopiperazinyl, morpholinyl, thiomorpholinyl, 2-oxomorpholinyl, azepinyl, diazepinyl, oxapinyl, thiazepinyl, oxazolidinyl, thiazolidinyl, dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, benzopyranyl, benzopyranonyl, benzodihydrofuranyl, benzodihydrothienyl, pyrazolopyrimidonyl, azaquinazolinoyl, thienopyrimidonyl, quinazolonyl, pyrimidonyl, benzoxazinyl, benzoxazinonyl, benzothiazinyl, benzothiazinonyl, thieno piperidinyl, pyridyl, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, isothiazolyl, imidazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, benzofuranyl, benzothienyl, indolinyl, indolyl, azaindolyl, azaindolinyl, pyrazolopyrimidinyl, azaquinazolinyl, pyridofuranyl, pyridothienyl, thienopyrimidyl, quinolinyl, pyrimidinyl, pyrazolyl, quinazolinyl, pyridazinyl, triazinyl, benzimidazolyl, benzotriazolyl, phthalazynil, naphthylidinyl, purinyl, carbazolyl, phenothiazinyl, phenoxazinyl, benzoxazolyl, benzothiazolyl groups.

6. The compounds of formula (I) selected from

N-(benzyloxy)-2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-*c*-(3-(9H-carbazol-9-yl)propyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(piperidin-1-yl)methanone;

(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)(thiomorpholino)methanone;

(1,1-dioxidothiomorpholino)(2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxan-2-yl)methanone;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-(piperidin-1-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-thiomorpholinoethyl)-1,3-dioxane-2-carboxamide;

N-(2-(1,1-dioxidothiomorpholino)-2-oxoethyl)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-morpholino-3-oxopropyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-(((tetrahydro-2H-pyran-4-yl)methyl)amino)propyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-thiomorpholinopropyl)-1,3-dioxane-2-carboxamide;

N-(3-(1,1-dioxidothiomorpholino)-3-oxopropyl)-2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-3-(piperidin-1-yl)propyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-(4-methylpiperazin-1-yl)-3-oxopropyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-phenyloxazol-4-yl)methyl)-N-(3-oxo-1-phenylbutan-2-yl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(piperidin-1-yl)methanone;

(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)(thiomorpholino)methanone;

(1,1-dioxidothiomorpholino)(2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-1,3-dioxan-2-yl)methanone;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-(4-methylpiperazin-1-yl)-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-thiomorpholinoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-(piperidin-1-yl)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(3-oxo-1-phenylbutan-2-yl)-1,3-dioxane-2-carboxamide;

2-methyl-5-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)-N-(2-oxo-2-((3-oxo-1-phenylbutan-2-yl)amino)ethyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(p-tolyl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

(5-((2-(tert-butyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*t*-((5-methyl-2-(5-methylthiophen-2-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

N-benzyloxy-2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*c*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(pyridin-4-yl)oxazol-4-yl)methyl)-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

N-benzyloxy-2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxane-2-carboxamide;

1-(2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)-N-((tetrahydro-2H-pyran-4-yl)methyl)methanamine;

(2-methyl-5-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*c*-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-t-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

5-*c*-(3-(9H-carbazol-9-yl)propyl)-N-hydroxy-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*c*-(3-(10H-phenothiazin-10-yl)propyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(hydroxy)-5-*c*-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(hydroxy)-5-*t*-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-(2-oxo-2-(((tetrahydro-2H-pyran-4-yl)methyl)amino)ethyl)-1,3-dioxane-2-carboxamide;

(5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-N-(2-morpholino-2-oxoethyl)-1,3-dioxane-2-carboxamide;

(5-((3-(tert-butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

N-(benzyloxy)-5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

N-hydroxy-5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxane-2-carboxamide;

(5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

(5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(morpholino)methanone;

5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(5-*c*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

(5-*t*-((2-(4-methoxyphenyl)-5-methyloxazol-4-yl)methyl)-2-methyl-1,3-dioxan-2-yl)(4-methylpiperazin-1-yl)methanone;

N-(benzyloxy)-2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-(benzyloxy)-2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

N-hydroxy-2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxane-2-carboxamide;

(2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

(2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-1,3-dioxan-2-yl)(morpholino)methanone;

2-methyl-5-*c*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide;

2-methyl-5-*t*-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methyl)-N-((tetrahydro-2H-pyran-4-yl)methyl)-1,3-dioxane-2-carboxamide.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) as claimed in any of the preceding claims and a pharmaceutically acceptable carrier diluent or excipients.
8. A pharmaceutical composition according to claim 7 which is used for the treatment of dyslipidemia and related diseases.
9. A method of treating disorders caused by dyslipidemia and related diseases comprising administering to a patient in need thereof an effective amount of a compound of formula (I) according to any of the preceding claims or its pharmaceutical composition according to any of the preceding claims.
10. The use of a compound of formula (I) or its pharmaceutical composition according to any of the preceding claims for the manufacture of a medicament for the treatment of dyslipidemia and related diseases.
11. A medicine for the treatment of disorders caused by dyslipidemia and related diseases which comprises administering therapeutically effective amount of compound of formula (I) or its pharmaceutical composition as defined in any of the preceding claims to a patient or subject in need thereof.
12. Small molecules comprising the compounds according to any one of claims 1-6 which bind to the catalytic site of the PCSK9, as inhibitors of PCSK9.
13. Small molecules inhibitors of PCSK9 comprising the compounds according to any one of claims 1-6 which bind to the catalytic site of the PCSK9 protein.